p-Tau 212 Fact Sheet: A Key Blood-Based Biomarker for Early Alzheimer’s Detection
Explore how p-Tau 212 is transforming Alzheimer’s disease research and diagnostics. As an early-to-mid stage biomarker, p-Tau 212 offers high accuracy in detecting Alzheimer’s pathology—years before symptom onset. Powered by Simoa® technology, this biomarker is validated in plasma, CSF, and serum, providing ultra-sensitive detection for both sporadic and Down Syndrome-associated Alzheimer’s disease.
What You’ll Learn:
- The biological significance of p-Tau 212 in Alzheimer’s progression
- How p-Tau 212 supports early detection, disease staging, and therapeutic monitoring
- Key research applications for clinical trials, cohort stratification, and precision diagnostics
Download the fact sheet now to see how p-Tau 212 complements biomarkers like p-Tau 205, p-Tau 217, and BD-Tau in advancing Alzheimer’s disease research.